Mergers & AcquisitionsMedium•19 October 2026•
1 min read
Merck KGaA Offers to Acquire Silence Therapeutics for $1.3 Billion
Key Facts
1Merck KGaA offered to acquire Silence Therapeutics for $20.00 per share in cash, valuing the deal at approximately $1.3 billion.
2Silence Therapeutics shares surged 125.58% to $19.58, closing in on the proposed offer price.
3Law firm Halper Sadeh LLC is investigating the fairness of the $20.00 cash offer to Silence Therapeutics shareholders.
Merck KGaA offered to acquire Silence Therapeutics for $20.00 per share in cash, valuing the deal at approximately $1.3 billion according to Financial Modeling Prep. Silence Therapeutics shares surged 125.58% to reach $19.58, closing in on the proposed offer price. Law firm Halper Sadeh LLC has launched a legal investigation to assess the fairness of the cash offer to shareholders.
SLN closed at $19.58 on October 19, 2026, leaving a narrow gap of approximately 2.2% below the $20.00 acquisition target. Meanwhile, MKKGY closed at $32.27 on October 19, 2026. Merck KGaA seeks to integrate Silence's siRNA therapies into its rare-disease pipeline through this transaction.